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Abstract
Introduction: It is commonly known that glucocorticoids exert a significant effect on haemostasis. Studies that have analysed the plasmatic 
coagulation system and fibrinolysis parameters in hypercortisolaemic patients are abundant. Platelet function, which plays a vital role in 
primary haemostasis, is much less clear in this context. 
We aimed at assessing platelet function in endogenous hypercortisolaemic patients. 
Material and methods: Twenty-five hypercortisolaemic patients were included in the study. Twelve of them were diagnosed with overt 
Cushing’s syndrome (OCS) and 13 had subclinical Cushing’s syndrome (SCS). Thirty healthy volunteers comprised the control group. In 
all subjects platelet function parameters were examined: ADP- and collagen-induced platelet aggregation (ADP-IPA and Col-IPA, respec-
tively), IMPACT R (expressed as percentage of surface covered (SC) by platelets and average size (AS) of the adhering particles in μm2), 
as well as closure time (CT) after platelet activation with agonists: ADP and Col or Col and epinephrine (EPI). The statistical significance 
level was set at 0.05. 
Results: There was no significant difference in mean values of ADP-IPA, Col-IPA, Col/EPI CT, Col/ADP CT, SC, and AS between hypercor-
tisolaemic subjects and controls. No statistically significant differences in means of examined parameters were found between overt and 
subclinical Cushing’s syndrome patients. Furthermore, no statistically significant relationships were found between these parameters and 
hormonal indicators of hypercortisolism: 24-hour urinary cortisol excretion, morning and evening serum cortisol level, and overnight-test 
cortisol concentration.
Conclusions: In hypercortisolaemic patients no primary haemostasis disorders are present, as reflected by platelet adhesion and ADP- and 
collagen-induced aggregation measurements. (Endokrynol Pol 2015; 66 (3): 207–213)
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Streszczenie
Wstęp: Powszechnie wiadomo, że glikokortykoidy to grupa hormonów wykazująca szczególny wpływ na układ hemostazy. Badania 
oceniające osoczowy układ krzepnięcia i fibrynolizy u pacjentów z hipekortyzolemią są dość liczne. Zdecydowanie więcej niejaności 
pozostawia wpływ hiperkortyzolemii na funkcję płytek krwi, odgrywających kluczową rolę w hemostazie pierwotnej. 
Celem pracy była ocena funkcji płytek krwi u pacjentów z endogenną hiperkortyzolemią.
Materiał i metody: Badaniami objęto 25 chorych z endogenną hiperkoryzolemią. U 12 chorych rozpoznano pełnoobjawowy, a u 13 — 
subkliniczy zespół Cushinga. Trzydziestu zdrowych ochotników dobranych odpowiedno pod względem płci i wieku stanowiło grupę 
kontrolną. U wszystkich pacjentów oznaczono następujące parametry: agregację płytek krwi po stymulacji ADP i kolagenem (odpowiednio: 
ADP-IPA i Col-IPA), IMPACT R (wyrażony jako odsetek powierzchni płyty testowej pokryty płytkami krwi (SC) oraz średnia wielkość 
(AS) agregatów płytkowych w μm2 ), będący miarą adhezji płytek krwi; jak również czas okluzji (CT) po aktywacji płytek ADP i Col lub 
Col i epinefryną (EPI). Poziom istotności statystycznej wynosił 0,05
Wyniki: Nie wykazano znamiennych różnic pomiędzy grupą osób z hiperkortyzolemią a grupą kontrolną w średnich wartościach ADP-
-IPA, Col-IPA, Col/EPI CT, Col/ADP CT, SC i AS. Nie stwierdzono również znamiennych różnic w badanych parametrach pomiędzy grupą 
pacjentów z pełnoobjawową hiperkortyzolemią a subklinicznym zespołem Cushinga. Co więcej nie stwierdzono znamiennych zależności 
pomiędzy badanymi parametrami a hormonalnymi wykładnikami stopnia nasilenia hiperkortyzolemii, takimi jak: dobowym wydalaniem 
kortyzolu z moczem, porannym i wieczornym stężeniem kortyzolu w surowicy oraz w teście „over night”.
Wnioski: U pacjentów z endogenną hiperkortyzolemią nie stwierdza się zaburzeń hemostazy pierwotnej wyrażonej adhezją oraz agre-
gagacją płytek krwi po ADP i kolagenie. (Endokrynol Pol 2015; 66 (3): 207–213)
Słowa kluczowe: hemostaza pierwotna; czynniki krzepnięcia; zespół Cushinga; subkliniczny zespół Cushinga
This work was supported by Medical University of Gdańsk funds.
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Since many ambiguities remain, platelet function in 
hypercortisolaemic patients should be investigated 
more closely.
We aimed at assessing platelet function in endog-
enous hypercortisolaemic patients as well as verifying 
associations between possible primary haemostasis 
disorders and hormonal parameters. 
Material and methods
The study was approved by the ethics commit-
tee of the Medical University of Gdańsk, Poland 
(NKBBN/43/2013). 
In this prospective study 25 endogenous hypercorti-
solaemic patients were included, 21 women and 4 men, 
mean age 56.7 ± 11.9 years, who were hospitalised in 
the Department of Endocrinology and Internal Medi-
cine of the Medical University of Gdańsk or monitored 
at the department’s outpatient centre. Exclusion criteria 
encompassed patients with an acute or chronic symp-
tomatic infection, connective tissue diseases, thrombo-
cytopaenia, decreased activity of coagulation factors 
VIII and von Willebrand, women treated with oral 
contraceptives and hormonal replacement therapy, and 
individuals who used non-steroid anti-inflammatory or 
anti-platelet drugs in the two-week period preceding 
the examinations. Endogenous hypercortisolism was 
diagnosed in all patients. ACTH-dependent Cushing’s 
syndrome (CS) was diagnosed in 10 patients: 6 had 
a corticotropinoma, in 2 patients CD recurred after sur-
gery, and in 2 patients further ectopic ACTH secretion 
was present. In 15 subjects a hormonally active adrenal 
tumour was found: 2 subjects displayed overt hyper-
cortisolism due an adrenocortical carcinoma, while the 
remaining patients had an adrenal adenoma and met 
the criteria of subclinical Cushing’s syndrome (SCS). In 
all subjects physical examination and hormonal tests 
were performed. CS was diagnosed in patients with 
clinical hypercortisolaemic features: plethora, moon 
face, buffalo hump, central obesity, proximal muscle 
atrophy, and abnormalities in hormonal examinations: 
lack of cortisol suppression in the overnight, 1-mg- 
-dexamethasone test, as well as two-day dexametha-
sone suppression test, lack of circadian cortisol secre-
tion rhythm, and elevated 24-hour free urinary cortisol 
excretion. In adrenal-dependent CS, ACTH levels were 
suppressed (£ 10 pg/mL), while pituitary-dependent 
CS had inadequately elevated morning ACTH levels, 
no circadian ACTH secretion rhythm, and a typical re-
sponse in the corticotrophin-releasing hormone (CRH). 
As defined, SCS was diagnosed in patients with an 
incidental adrenal mass revealed in a CT abdominal 
scan, who did not have typical physical features of 
CS, and who exhibited endogenous hypercortisolism 
Introduction
It is commonly known that glucocorticosteroids exert 
a significant effect on haemostasis [1–3]. A plethora 
of studies confirms these hormones’ influence on 
haemostasis and fibrinolysis, which leads to increased 
prevalence of thromboembolic events [4–5]. On the 
other hand, in Cushing’s syndrome patients, skin 
diathesis is often observed, which appears to be con-
nected with the steroid’s damaging effect on the blood 
vessel walls [3].
Haemostasis disorders observed in overt hypercorti-
solaemic patients are multifaceted. Currently, no doubt 
remains concerning the elevated activity of coagula-
tion pathway as well as fibrinolysis inhibition [6–15]. 
The effect of hypercortisolaemia on platelet function 
is much less clear.
Platelets have two major roles in haemostasis. First, 
they form the haemostatic platelet plug. Second, they 
participate in the activation of the coagulation path-
way by delivering negatively charged phospholipids 
from the inner to the outer layer of the thrombocyte 
membrane. In the process of coagulation three steps of 
thrombocyte action can be listed: adhesion, secretion, 
and aggregation. Collagen exposition from a damaged 
vessel wall leads to platelet adhesion through specific 
collagen receptors in the platelet cellular membrane 
and von Willebrand factor (vWF); during this step 
platelet activation takes place [16, 17]. This process, in 
turn, leads to the secretion of biologically active sub-
stances such as thrombin, collagen, platelet activating 
factor (PAF), adenosine diphosphate (ADP), throm-
boxane A2, and serotonin, which promote platelet 
aggregation and inhibit natural anticoagulation factors 
of endothelial cells. Optimal platelet aggregation also 
requires fibrinogen and calcium ions. Apart from the 
platelet-activating agonists mentioned, there are other 
factors with a minor aggregative ability, which increase 
the effect of other agonists [17]. One instance of such 
a compound is epinephrine. Under the influence of 
activating factors, negatively charged phospholipids 
phosphatidylserine and phosphatidylethanolamine 
are exposed, which bind with calcium ions and car-
bonyl groups of coagulation factors.
So far, few reports have been published on the effect 
of corticosteroids on platelet function, most of them 
were veterinary medicine studies [16, 18], and their 
results indicate a suppressive effect of exogenous glu-
cocorticosteroids on blood platelet aggregation in ani-
mals [16, 19]. These observations contrast with reports 
on megakaryocyte function in Cushing’s disease (CD) 
patients. It was shown, namely, that hypercortisolism 
may lead to vWF multimers overexpression, which 
can spontaneously trigger platelet aggregation [6]. 
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in hormonal tests [20–22]. Cortisol serum level of 
140 nmol/L and above in the overnight 1-mg-dexameth-
asone suppression test was a sufficient criterion for the 
diagnosis of SCS. Patients with cortisol concentrations 
between 50 and 140 nmol/L in this test also had to have 
met at least one of the following criteria: abnormal 
serum circadian cortisol secretion, decreased morning 
ACTH concentration (£ 10 pg/mL), and/or increased 
24-hour free cortisol urinary excretion. These diagnostic 
criteria were applied to our patients [23]. Moreover, 
in all SCS patients cortisol was not fully suppressed 
(> 50 nmol/L) in the two-day low-dose dexamethasone 
test (0.5 mg every 6 hours). 
In all adrenal-dependent hypercortisolaemic pa-
tients a mass of the gland was found in a targeted 
adrenal CT scan, while in all CD subjects MR of the 
pituitary revealed a microadenoma. All hormonal as-
says were performed in the same laboratory with freely 
available kits. ACTH serum level was determined using 
a solid-phase, two-site sequential chemiluminescent 
immunometric assay Immulite®1000ACTH by Sie-
mens. Serum and urinary cortisol levels were tested 
with a Chemiluminescent Microparticle Immunoassay 
(CMIA), specifically — a Cortisol Reagent Kit on an Ab-
bott’s Architect device.
Our control group comprised 30 healthy individuals 
who were matched for age, sex, and BMI (24 women 
and 6 men, mean age 49.2 ± 11.6 years). In all controls 
full cortisol suppression in the overnight 1-mg-dexa-
methasone was recorded (i.e. serum level < 50 nmol/L), 
which excluded subclinical hypercortisolism. No study 
participant received drugs altering platelet function. 
Fasting blood samples were acquired in the morning 
from a cubital vein. 
In all subjects the following parameters were exa-
mined immediately: ADP- and collagen-stimulated 
platelet aggregation, IMPACT R, and PFA 100. 
A multiplate electron aggregometry system, which 
uses impedance aggregation, was applied to assess 
ADP- and collagen-induced platelet aggregation 
(ADP-IPA and Col-IPA, respectively). Roche Diagnos-
tics (Germany) Multiplate system and designated kits 
were used. 
The PFA 100 (Platelet Function Analyser) is 
a microprocessor-controlled device that provides 
a measure of whole blood platelet related haemosta-
sis at high shear stress. In this method, the closure 
time (CT) of an aperture containing a nitrocellulose 
membrane coated with platelet agonists is measured. 
ADP and collagen or collagen and epinephrine (EPI) 
are agonists that activate platelets in this method [24]. 
The measure of platelet function in the PFA system 
reflects their adhesion and aggregation in full blood. 
In this study the PFA system and test assays Col/EPI 
and Col/ADP by Siemens Healthcare Diagnostics 
(Germany) were used.
Impact R measures platelet adhesion in whole blood 
in arterial flow conditions (1800 s–1;for 2 min.). Laminar 
flow over polystyrene surface of the wall is achieved 
according to the Cone and Plate principle [24, 25]. Re-
sults are expressed as percentage of surface covered 
(SC) by platelets and average size (AS) of the adherent 
particles in μm2 [24]. Tests here were performed using 
DiaHem (Switzerland) kit and reagents (DiaMed 
Impact-R test kit). 
In all representatives, the estimation of basic 
coagulation parameters, such as international nor-
malised ratio (INR), activated partial thromboplastin 
time (APTT), fibrinogen concentration, and complete 
blood count, was also determined with routinely 
used methods.
All statistical calculations were performed with the 
use of STATA 13.1 software (StataCorp, Texas, USA). 
Prior to analysis, data were screened for potential er-
rors. Standard descriptive statistics were computed. 
Some variables were transformed before parametric 
analyses. Comparisons between groups were carried 
out using ANOVA test. Scheffe post-hoc test was used 
when indicated. Correlations were evaluated using 
Spearman rank correlation method. The level of statisti-
cal significance was set at 0.05. 
Results
Hormonal results are presented in Table I. Clearly, the 
highest serum cortisol concentrations and the hor-
mone’s highest urine excretion, plainly diverging from 
those of other subjects, were stated for ectopic ACTH 
synthesis and adrenal cortex cancer patients. 
A comparison of studied parameters between hyper-
cortisolaemic patients and controls is shown in Table II. 
Mean values of ADP-IPA and Col-IPA in hypercorti-
solaemic subjects were not significantly different from 
those of controls (P = 0.127 and P = 0.630, respectively). 
Also, no statistically significant differences in mean Col/ 
/EPI CT (P = 0.359), Col/ADP CT (P = 0.863), SC 
(P = 0.405), and AS (P = 0.209) were found between 
patients and controls.
Taking into account the possible influence of neoplas-
tic disease on thrombocyte function, a separate analysis 
was carried out for patients with adrenal cortex cancer 
and ectopic ATCH-secreting patients, who had the 
greatest abnormalities in hormonal examinations. No 
differences in mean values of studied parameters were 
found in patients with OCS due to malignancies and 
in the remaining hypercortisolaemic patients (Table II).
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Further analysis was performed, in which OCS and 
SCS patient subgroups were compared to healthy con-
trols. No statistically significant differences of studied 
parameters were recorded (in the OCS versus controls 
comparisons: ADP-IPA: P = 0.642, Col-IPA: P = 0.946, 
CT-Col/EPI: P = 0.509, CT-Col/ADP: P = 0.850, SC: 
P = 0.913, AS: P = 0.733; for SCS versus controls: 
ADP-IPA: P = 0.325, Col-IPA: P = 0.562 CT-Col/EPI: 
P = 0.945, CT-Col/ADP: P = 0.964, SC: P = 0.670, AS: 
P = 0.476) (Table III).
Moreover, no statistically significant differences 
in means of examined parameters were found be-
tween overt and subclinical CS patients: ADP-IPA: 
P = 0.904, Col-IPA: P = 0.503, CT-Col/EPI: P = 0.773, 
CT-Col/ADP: P = 0.777, SC: P = 0.903, AS: P = 0.943 
(Table III).
Next, we analysed the relation between ADP-IPA, 
Col-IPA, CT-Col/EPI, CT-Col/ADP, SC, AS values, and 
hormonal test results illustrating the degree of hy-
percortisolaemia: 24-hour urinary cortisol excretion, 
morning and late evening serum cortisol level, and 
overnight-test cortisol concentration. No statistically 
significant relationships were found between these 
parameters (Table IV). 
Discussion
Studies that have analysed the plasmatic coagulation 
system and/or fibrinolysis parameters in endogenous 
hypercortisolaemic patients are abundant. Platelet func-
tion, which plays a vital role in primary haemostasis, is 
much less clear in this context. Most reports so far have 
investigated the effect of synthetic steroids on plate-
let count, while there are far fewer in which platelet 
function was analysed, and these were predominantly 
performed in veterinary research [16, 18]. Moreover, 
until now, the majority of studies have investigated the 
influence of exogenous steroids on platelet aggregation. 
In our research the effect of endogenous hypercortisol-
aemia on platelet adhesion as well as aggregation was 
tested. Furthermore, in the current study platelet func-
tion was examined in whole blood, i.e. in the presence 
of blood cells, which can modulate platelet response to 
aggregation stimuli. 
Table I. Hormonal characteristics of overt and subclinical hypercortisolaemic patients
Tabela I. Charakterystyka hormonalna pacjentów z pełnoobjawową i subkliniczną hiperkortyzolemią
Laboratory examination OCS SCS Normal ranges
Mean SD Mean SD
Serum cortisol [nmol/L]: morning 810.8 848.5 302.5 98.1 101–536
Serum cortisol [nmol/L]: night 654.4 701.7 203.5 93.4 –
Serum cortisol in an overnight suppression test  
(1 mg dexamethasone) [nmol/L]
662.3 980.3 149.2 103.9 < 50
24-hour urinary free cortisol excretion [nmol/24 h] 3699.5 7442.4 218.3 115.9 12–486
Plasma ACTH [pg/mL]: morning 70.5 69.9 13.8 5.9 15–46 
Serum DHEA-S [µg/dL] 243.4 252.8 41.0 40.2 80–560
Table II. Parameters of platelet aggregation and adhesion in hypercortisolaemic patients (whole group and after exclusion of 
malignant neoplasm) and healthy controls
Tabela II. Parametry agregacji i adhezji płytek krwi u pacjentów z hiperkortyzolemią (u wszystkich chorych oraz po wyłączeniu 
pacjentów z chorobą nowotworową) i w grupie kontrolnej
CS (OCS and SCS) CS after exclusion of neoplasm Control group
Mean SD Mean SD Mean SD
ADP-IPA [U] 83.5 32.9 86.4 32.2 70.1 31.3
Col-IPA [U] 65.4 27.3 68.3 27.0 68.7 23.2
CT-Col/EPI [s] 145.5 93.2 148.4 94.3 127.0 52.6
CT-Col/ADP [s] 106.3 75.4 102.6 70.1 103.3 49.4
SC (%) 12.8 4.1 12.7 3.8 11.9 3.8
AS [µm2] 53.4 23.6 49.3 19.7 45.5 22.4
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We found no statistically significant differences in 
platelet function parameters between hypercortisolae-
mic patients and healthy controls. This result was found 
both for ADP, collagen-stimulated aggregation, Impact R, 
and occlusion time with Col/ADP and Col/EPI assays. 
It is difficult to compare our results with those of other 
groups due to the scarcity of such research. Casonato et 
al. examined 20 CS patients and found elevated spon-
taneous platelet aggregation as well as hyper-reactivity 
in ristocetin-induced aggregation. They demonstrated 
that in active hypercortisolaemic patients over-expres-
sion of abnormally high molecular weight multimers 
takes place, which are capable of inducing spontaneous 
platelet aggregation that is found physiologically only in 
the cellular compartments and not in the plasma [6, 26]. 
This explains the elevated ristocetin aggregation. 
Studies where ADP- and collagen-induced aggrega-
tion were examined mainly concern the influence of 
exogenous steroids on these parameters; the results 
are discordant and thus inconclusive. Liverani et al. 
demonstrated in vitro the presence of the glucocor-
ticoid receptor on blood platelets, and an inhibitory 
effect of prednisolone on their adhesion and aggre-
gation, and therefore on the formation of the platelet 
plug as well as on the interaction with monocytes [27]. 
On the other hand, Rosenfeld et al. stated elevated 
collagen-induced platelet aggregation following infu-
sion of stress hormones, among them hydrocortisone 
[28]. A direct effect of exogenous glucocorticosteroids 
on platelet activation was recorded in studies by Jilma 
et al., who found a statistically significant increase in 
P-selectin, a marker of blood platelet activation, 
Table III. Parameters of platelet aggregation and adhesion in OCS and SCS patients versus controls
Tabela III. Parametry agregacji i adhezji płytek krwi u pacjentów z OCS i SCS w porównaniu z grupą kontrolną
OCS SCS Controls
Mean SD Mean SD Mean SD
ADP-IPA [U] 80.5 33.1 86.3 33.8 70.1 31.3
Col-IPA [U] 71.6 32.2 59.8 21.6 68.7 23.2
CT-Col/EPI [s] 156.6 90.0 135.2 98.6 127.0 52.6
CT-Col/ADP [s] 115.6 88.3 97.7 63.8 103.3 49.4
SC (%) 12.5 4.9 13.1 3.3 11.9 3.8
AS [µm2] 51.8 26.1 54.9 22.0 45.5 22.4
Table IV. Coefficients and p values of correlations between examined platelet function and hormonal parameters (Spearman 
rank correlation method)
Tabela IV. Współczynniki korelacji pomiędzy badanymi parametrami, oceniającymi funkcję płytek krwi a parametrami 
hormonalnymi wg Spermana oraz poziomy istotności statystycznej p 
Serum cortisol morning Serum cortisol night Serum cortisol in “overnight” test Urinary cortisol excretion
ADP-IPA –0.26 –0.26 –0.09 –0.15
p = 0.204 p = 0.216 p = 0.659 p = 0.463
Col-IPA 0.02 –0.17 –0.05 0.06
p = 0.937 p = 0.415 p = 0.819 p = 0.784
CT-Col/EPI 0.21 0.16 0.02 0.34
p = 0.312 p = 0.459 p = 0.919 p = 0.100
CT-Col/ADP –0.08 –0.01 –0.03 0.05
p = 0.710 p = 0.971 p = 0.892 p = 0.805
SC –0.08 0.07 –0.10 –0.14
p = 0.706 p = 0.728 p = 0.624 p = 0.515
AS –0.12 0.05 –0.04 0.10
p = 0.581 p = 0.802 p = 0.864 p = 0.649
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in healthy men after short-term administration of dexa-
methasone in high doses [29]. 
Animal models, however, indicate impaired platelet 
ADP-stimulated aggregation after hydrocortisone infu-
sion. Casella et al. suggest that hydrocortisone modu-
lates the interaction between ADP and the appropriate 
receptor, as well as phospholipase A2 and phospholi-
pase C activation by thromboxane, PAF, and/or ADP 
[16]. These results were not confirmed by Schuerholz 
et al., who found no alteration of platelet receptor 
expression by hydrocortisone in septic patients [30]. 
Taking into account the results of the above-mentioned 
reports, the sort of glucocorticosteroid and its dose 
should be investigated as the reason for these contrast-
ing findings. [16, 19]. 
It is understandable, therefore, that our results on 
the effect of endogenous hypercortisolism on blood 
platelet function should not be set on equal footing 
with reports on exogenous corticoids. The only report 
on ADP-, collagen-, and adrenaline-induced aggrega-
tion in CD patients was published in 1985 [31]. Ikkala 
et al. assessed primary haemostasis parameters in 12 
endogenous hypercortisolaemic patients. Similarly to 
our results, no statistically significant disorders of the 
above parameters were found. ADP- or adrenaline-
induced aggregation was borderline or subnormal in 
five patients, while only in one was impaired collagen-
induced aggregation recorded. Our study is the first 
to assess platelet adhesion in vascular flow conditions 
(Impact R) as well as occlusion time in the PFA system, 
which analyses adhesion and aggregation in whole 
blood in endogenous hypercortisolaemic patients. It 
should be stressed that ADP- and collagen-stimulated 
platelet aggregation was tested using an impedance 
method, which reflects physiological conditions. 
In our study no significant differences in platelet 
function were found between overt and subclinical CS 
patients, and neither did we find any relation between 
platelet function parameters and hormonal hyper-
cortisolaemic parameters (i.e. 24-hour urinary cortisol 
excretion, morning and evening serum cortisol level, 
overnight-test cortisol concentration). This supports 
the result that hypercortisolism does not influence the 
studied parameters. 
The authors recognise that the patient sample 
studied here is small and heterogeneous. The low in-
cidence of endogenous Cushing’s syndrome, the fact 
that patients treated with platelet function-altering 
medication had to be excluded, and the necessity of 
performing platelet function tests directly after drawing 
blood were the main reasons for the size of our sample. 
These difficulties probably explain the scarce body of 
research on primary haemostasis, particularly platelet 
function, in hypercortisolaemic patients. 
Taking into account the possible effect of malignant 
neoplasm on platelet function, patients with adreno-
cortical cancer and ectopic ACTH-secreting ones were 
analysed separately. No differences in platelet function 
were found for them compared to other hypercortisol-
aemic subjects. 
The results of the previous reports and our study 
suggest that there are no disorders in ADP- and colla-
gen-stimulated platelet aggregation or platelet adhesion 
tested in the PFA and Impact R systems in endogenous 
hypercortisolism. 
Conclusions
In Cushing’s syndrome patients, no primary haemo-
stasis disorders are present as reflected by platelet 
adhesion and ADP- and collagen-induced aggregation 
measurements. 
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